TCGA-GC-A3WC-01A-31R-A22U-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 17.73981603
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.510
- INTERFERON_GAMMA_RESPONSE+0.490
- ALLOGRAFT_REJECTION+0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.270
- G2M_CHECKPOINT+0.250
- COMPLEMENT+0.240
- KRAS_SIGNALING_DN+0.220
- KRAS_SIGNALING_UP+0.180
Top 10 suppressed
- TGF_BETA_SIGNALING-0.370
- DNA_REPAIR-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.270
- PEROXISOME-0.230
- HYPOXIA-0.210
- GLYCOLYSIS-0.190
- ESTROGEN_RESPONSE_EARLY-0.180
- NOTCH_SIGNALING-0.180
- OXIDATIVE_PHOSPHORYLATION-0.160
- PROTEIN_SECRETION-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_10_0136_B1_S95 | — | D | 0.802 |
| 2 | 7d3b4d06-1249-4a85-a66a-387d4e2e2cb2 | — | — | 0.801 |
| 3 | TCGA-BH-A18V-06A-11R-A213-07 | — | D | 0.793 |
| 4 | TCGA-AR-A1AW-01A-21R-A12P-07 | — | D | 0.790 |
| 5 | TCGA-A2-A0ST-01A-12R-A084-07 | — | D | 0.788 |
| 6 | C3L-02969 | — | cohortSQ2 | 0.780 |
| 7 | C3N-02922 | — | cohortMD2 | 0.775 |
| 8 | TCGA-E9-A1ND-01A-11R-A144-07 | — | E | 0.775 |
| 9 | TCGA-C8-A12V-01A-11R-A115-07 | — | D | 0.771 |
| 10 | b03d2223-38c1-4bb3-be8b-27db05f87b66 | — | — | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.070 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.060 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |